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Gut microbiota plays a significant role in human health and energy balance, and provides protection against
disease states. An altered balance between microbiota and its host (dysbiosis) would appear to contribute to the
development of Inflammatory Bowel Disease (IBD), Crohn’s Disease (CD) and Ulcerative Colitis (UC). CD and UC are
chronic inflammatory diseases of the gastrointestinal tract that occur in genetically susceptible individuals. Several
genes of susceptibility are involved in inappropriate activation of intestinal mucosal immune responses, such as
NOD2, IL-23 R and ATG16L1. In host susceptibility, immune dysregulation determines loss of tolerance against
resident intestinal microbiota. Vast potential exists for manipulating the gut microbiota for therapeutic effect, such
as use of probiotics and fecal microbiota transplantation. More research is needed to rationally target microbe-
directed therapies.
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The human gut is sterile at birth but immediately after and
during infancy, it is colonized by numerous types of micro-
organisms with temporal and inter-individual variations,
which can be influenced by environmental factors [1].
The adult human intestinal microbiota contains around
1014 bacterial cells and up to an estimated 1,000 different
bacterial species [2], resident at any time in the gastro-
intestinal tract. Bacterial numbers range from very low
levels in the stomach to high levels of luminal contents in
the human colon. There are four predominant species:
Firmicutes, Bacteroides, Proteobacteria and Actinobacteria.
The most abundant bacteria phyla found in the healthy
human large intestine are Gram-negative Bacteroidetes
and Gram-positive low-GC Firmicutes [3].
The gut microbiota performs a number of critical roles
in the adult: metabolism of dietary components and chol-
esterol, enterohepatic cycling of bile acids, vitamin synthe-
sis, intestinal motility, immune system modulation [4].
Preserving eubiosis is important for maintaining the in-
tegrity of the intestinal epithelium [5] and contributing to
antimicrobial defenses. Intestinal epithelial cells (IECs)
provide a physical barrier between luminal microbes and* Correspondence: romanoc@unime.it
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unless otherwise stated.underlying intestinal tissues to control defense and toler-
ance [6]. IECs express pattern recognition receptors, they
can recognize microbial pathogen-associated molecular
patterns and respond to intestinal microbes through secre-
tion of cytokines and antimicrobial proteins. Furthermore
they can up-regulate surface molecules [7]. The presence
of IgA reduces intestinal proinflammatory signals and
drives diversity in gut microbiota [8]. A defective antibac-
terial, genetically driven barrier allows translocation and
regulation of the microbiota. Commensal bacteria can
have an anti-inflammatory effect on the developing im-
mune system; for example, in the neonatal period T helper
type 2 response is predominant [9]. Host–microbe inter-
action is a two-way dialogue; in healthy conditions, bal-
anced mechanisms regulate the host’s immunological
tolerance to continuous stimulus of resident gut micro-
biota and their metabolic end products. Human nutri-
tional components and dietary patterns cleary impact
microbial composition and function of intestine. Long-
term differences in diet seem to affect gut microbiota, as
digestion of diet with fiber and plants component, without
demonstrated role in the pathogenesis of IBD [10].Dysbiosis in IBD: cause or effect of the disease?
Dysbiosis is defined as an abnormal ratio of beneficial
and aggressive bacterial species. A more recent studyLtd. This is an Open Access article distributed under the terms of the Creative
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remains unclear whether dysbiosis is a cause or a conse-
quence of the mucosal inflammation [11].
Recent metagenomic studies have analyzed microbial
compositions in IBD, suggesting that not only is the
quantity of commensal bacteria reduced but also the
quality and composition of the microbiota are altered
with reduction of Firmicutes and Bacteroidetes. It has
been reported that in IBD patients compared to healthy
controls there is an abnormal colonization of the ileal
mucosa by Adherent/Invasive E. coli (AIEC) [12] and re-
duced ileal mucosal concentrations of Faecalibacterium
prausnitzii, member of Clostridium subsets IV. This
condition can be respectively associated to severity of
ileal disease and predictive of high risk for early reactiva-
tion of ileal Crohn’s disease [13]. Recently, a molecular
subset of Bacteroides fragilis, termed enterotoxigenic B.
fragilis has been identified in abnormal concentrations
in patients with active IBD [14].
There is also a different microbiota composition between
inflamed and non-inflamed mucosa [10] with loss of toler-
ance and defectiveness in the production or function of
anti-bacterial peptides, such as defensins by Paneth cells. It
has been demonstrated that alpha-defensin production is
reduced in ileal CD [15], while antibacterial peptide ex-
pression is reduced in colonic CD [16]. These alterations
cause loss of tolerance to commensal flora, and to amplifi-
cation and maintenance of inflammatory response to intes-
tinal pathogens. In trying to establish a pathogenic role of
dysbiosis in IBD, microbial imbalance may be a trigger for
a range of mechanisms determining low intraluminal levels
of butyrate, down-regulation of epithelial tight junction
protein expression and at least increased epithelial per-
meability. Epithelial barrier dysfunction brings about in-
creased bacterial translocation through the lamina propria,
which is worsened by decreased luminal IgA and defensinFigure 1 Dysbiosis and intestinal inflammation.concentrations (Figure 1) [17]. Killing of bacteria reaching
the lamina propria, through the “leaky” epithelium, is also
impaired by a genetically predisposed defective macro-
phage phagocytosis. Ineffective bacterial clearance leads to
excessive TLR stimulation, secretion of pro-inflammatory
cytokines and activation of innate and T-cell mediated im-
mune responses. This disrupted mechanism of tolerance
in epithelial cells may recognize dysbiosis as a primum
movens of induction of intestinal inflammation by com-
mensal bacteria and pathogens.
One agent that has raised a great deal of controversy
is Mycobacterium avium subspecies paratuberculosis
(MAP), agent of chronic granulomatous enterocolitis in
ruminants, has been considered a possible etiologic
agent of CD [18]. Prevalence studies of MAP in CD pa-
tients from many countries worldwide have reported
widely divergent results ranging from 0% to 100% [19].
The possible role of MAP has also been supported by
the identification of MAP DNA in media inoculated
with peripheral blood mononuclear cells (PBMC) from
patients with CD [20]. Kirkwood et al. found evidences
of MAP infection in 45% of children with CD, 35% of
children with UC, and 11% of non-IBD children. These
results support the hypothesis that MAP infection of in-
testinal tissue, perhaps associated with blood-borne
spread, may be implicated especially in the pathogenesis
of pediatric CD [21]. However, the failure of triple antimy-
cobacterial therapy has questioned whether this pathogen
is involved in the pathogenesis of CD [22].
One other enteric bacterial pathogen that has been
considered in the pathogenesis of IBD is Clostridium
difficile. Toxin A of C. difficile may have the ability to re-
activate IBD [23]. In a Polish retrospective study, Mir et al.
have examined the rate of C. difficile infection (CDI) in 123
new pediatric IBD patients and overall prevalence was
8.1%, significantly lower than in Poland but much higher
Comito et al. Italian Journal of Pediatrics 2014, 40:32 Page 3 of 6
http://www.ijponline.net/content/40/1/32than in the general population [24]. Other studies have
reported a low incidence of CDI in pediatric IBD [25,26],
but all studies support testing for C. difficile in suspected
cases of new onset or flare pediatric IBD, and new
biomarkers have been identified to distinguish C. difficile
colonization from diseases that need therapy [26].Genoma and microbioma in IBD
The insights obtained during genoma wide association
studies have shed new light on the interaction of bacteria
with the mucosal immune system and the pathways by
which intestinal microbiota may contribute to chronic
mucosal inflammation. Loss of function mutations in
NOD2 are responsible for dysregulation of ileal microflora
and of hypo-production of antimicrobial peptides, such as
defensins, and may increase disease susceptibility by alter-
ing interactions between ileal microbiota and mucosal im-
munity [27]. CD patients with NOD2 gene defects have an
impaired ability to recognize and process bacterial prod-
ucts, and this may lead to an inappropriately long immune
response. In 2006, Duerr et al. [17] showed that association
of variants of the interleukin IL-23 receptor gene with
both CD and UC confers strong protection against
CD. Some CD patients have variants of the ATG16L1 and
Immunity-related GTPase family M Protein (IRGM)
autophagy genes, implying a defective capacity to process
cell degradation products as well as bacteria, and to
eliminate pro-inflammatory stimuli [28].
Three exclusive theories have been proposed concerning
the implication of bacteria in the etiopathogenesis of IBD:
the first is related to an involvement of persistent patho-
gen, the second, an abnormally permeable mucosal barrier
leading to excessive bacterial translocation, and the third,
a breakdown in the balance between putative “protective”
as against “harmful” intestinal bacteria which can promote
inflammation.
The alteration of the balance of the microbiota by host
tissue due to environmental factors on the microbiota can
be considered as the basis of disease. Interestingly, a simi-
lar reduction in bacterial diversity has recently been noted
in the oral microbiota of children with CD, but not in
those with UC or healthy children. Only adult studies
examining biopsies from both active and quiescent UC
suggest a reduction in bacterial diversity. Early-onset IBD
(onset <6 years of age) and very early onset IBD (onset
<2 years of age) present a unique opportunity to study the
impact of immunological status, neutrophil role, gut
microflora, metabolic pathways, and environmental factors
on genetic predisposition and the natural history of IBD.
Disease phenotypes are primarily colonic with frequent
perianal and oral localization, and with a more rapid and
progressive disease course. Colectomy has been required
in a high percentage of children. It may be associated withimmunodeficiency states, neutrophil defect, metabolic dis-
ease and monogenic defects (IL-10) [29].
Implications for therapy
Dysbiosis can be considered an important pathogenetic
factor in IBD. Manipulation of the microbiota may be a
new therapeutic approach to IBD.
Probiotics and prebiotics
Probiotics have been described as “live microbial supple-
ments that beneficially affect the consumer by improving
intestinal microbial balance” [30]. The mechanisms of ac-
tion of the probiotics can be quite disparate. It has been
shown that they modulate the permeability of epithelial
barriers, alter the inflammatory potential of epithelial cells,
compete with pathogens for mucosal colonization, or dir-
ectly modify the activity of immune cells [31]. Recently,
IL-17–producing T-helper cells (Th17 cells) have been
regarded as crucial for the control of several chronic in-
flammatory diseases such as IBD. Th17 cells are abundant
in the intestine, and the development of these cells seems
to be regulated by dendritic cells and macrophages in the
lamina propria [32]. Thus, orally administered probiotics
(such as L. rhamnosus GG, a strong inducer of TGF-beta,
IL1-beta and IL-23) could affect the development of Th17
cells and ameliorate clinical symptoms [33].
Numerous small studies reported on the efficacy of pro-
biotics in pouchitis. Gosselink et al. [34] showed that first
episodes of pouchitis were observed significantly less fre-
quently in UC patients who received Lactobacillus rham-
nosus GG daily versus placebo (7% vs 29%). L. rhamnosus
GG has been demonstrated to inhibit TNF-α -mediated
apoptosis of intestinal epithelial cells [35].
A small open label trial in 2008 showed that mainten-
ance therapy for 34 children in remission from ulcerative
colitis (UC), with probiotic Escherichia coli Nissle 1917
(EcN) is as effective as mesalazine [36], confirming the
data of adult UC [37]. EcN has been demonstrated to have
pro-apoptotic effects on pro-inflammatory γδ-T cells,
which are increased in the blood of IBD patients [38,39].
VSL#3, a mixture of eight bacterial species, has been as-
sociated to maintenance of remission pouchitis [40] and
antibiotic-induced remission in UC. A pediatric trial dem-
onstrated significant efficacy of VSL#3 in the induction
and maintenance of remission in pediatric active UC.
Twenty-nine consecutive patients (mean age, 9.8 years)
with newly diagnosed UC were randomized to receive ei-
ther VSL#3 or an identical placebo associated to concomi-
tant steroid induction treatment and oral mesalazine
maintenance treatment. Patients treated with VSL#3 and
concomitant conventional therapy had a significantly
higher rate of remission compared with the group treated
only with conventional therapy, with a significantly lower
incidence of relapse within one-year follow-up. There
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VSL#3 [41].
Although mixtures of probiotic species have shown
some efficacy in treating IBD [42], they are not consid-
ered effective for intestinal homeostasis and can popu-
late the intestine only transiently. Overall, no consistent
benefits have been observed in CD patients.
A randomized placebo-controlled study provides evi-
dence that inflammation of the rectal mucosa in 31 chil-
dren with active distal UC can be reduced by local
administration of Lactobacillus reuteri ATCC55730 in
addition to standard oral mesalazine. Compared with the
placebo-treated group, the probiotic-treated group had
reduced Mayo scores (clinical and endoscopic features)
and histological scores. In this group, concentrations of
mucosal pro-inflammatory cytokines (IL-1b, TNF-α and
IL-8) decreased significantly, whereas anti-inflammatory
cytokine (IL-10) increased significantly [43].
Diet can influence the composition of the microbiota.
Dietary manipulation with prebiotics, non-digestible food
ingredients that stimulate the growth and/or activity of
bacteria in the digestive system, can promote the growth
of commensal bacteria (lactobacilli and bifidobacteria)
[44]. However, clinical trials are lacking in IBD patients,
because of high dropout rates due to troublesome side
effects, such as increased gas and bloating.
Nutritional therapy can improve the inflammatory
status of CD by restoring the composition of the muco-
sal microbiome. Recently, a case of CD gut microbiome
dysbiosis that responded to nutritional therapy has
been described [45]. However, these data need to be
confirmed by multicenter studies and possible clinical
trials.
Antibiotics
Antibiotics may have clinical efficacy in a subgroup of
IBD patients to targeted killing/stasis of bacteria. The
most used are amoxicillin, tetracycline, metronidazole,
neomycin or rifaximin. Clinical efficacy has been shown
in pouchitis. A meta-analysis in 2011 supported a role of
antibiotics in induction of remission of CD, UC and
perianal fistulae [46]. Significant variability exists in anti-
biotic use for children hospitalized with IBD exacerba-
tion, and further studies are needed to determine the
optimal antibiotic therapy for this condition [47]. Levine
and Turner [48], in a retrospective analysis, have dem-
onstrated that an 8 weeks course of azithromycin and
metronidazole may be effective in inducing clinical re-
mission in mild-moderate luminal CD in children and
young adults. However, prolonged administration of an-
tibiotics can be accompanied by systemic adverse ef-
fects and can induce CDI. Rifaximin, a polymer with
negligible intestinal absorption, has been shown to
modulate the colonic microbiota of patients with CD byincreasing the concentration of anti-inflammatory com-
mensal, such as Bifidobacteria and Faecalibacterium
prausnitzii. Furthermore, in a preliminary experience in
pediatric IBD, rifaximin appeared to be effective and well
tolerated [49].
Fecal microbiota transplantation
Fecal microbiota therapy (FMT) is a treatment that in-
volves transplanting the intestinal bacteria of a healthy
person to a person with the disease [50]. In literature,
the first use of FMT is described for treating pseudo-
membranous colitis, refractory to antibiotic therapy,
with good results [51]. Rubin et al has reported 79% re-
mission after nasogastrically delivered fecal transplant-
ation in a cohort of 74 patients with recurring CDI [52].
After FMT, the modification of the composition of the
microbiota can be seen with an increase in the presence
of the Bacteroidetes and Firmicutes species [53]. Several
randomized placebo-controlled clinical trials have con-
firmed that FMT is safe and effective for treating C. dif-
ficile infection [54,55], and a recent eradication of CDI
in a UC patient was described [56]. Nine cases of IBD
flares (8 UC and 1 CD) successfully treated with FMT in
IBD, without side effects have been reported [57-60].
Further studies are needed to understand what compo-
nents are most responsible for efficacy, and to clarify if it
is possible to develop an “artificial stool”, eliminating
theoretical infectious risks and unpleasantness [61].
Others
Other proposed therapeutic strategies include: blocking
attachment of adherent bacteria by several probiotic bac-
teria or bacterial components (such as fibers and emulsi-
fiers) [62] and enhancing defective bacterial killing in
genetically susceptible hosts by Granulocyte-macrophage
colony-stimulating factor [63].
Conclusions and perspectives
An increased understanding of the molecular mechanisms
that modulate the innate immune response to bacteria
and antigens in the intestine is important to better define
the pathogenesis of IBD. However, it is not yet clear
whether dysbiosis contributes to the development of IBD
or is instead a consequence of the disease. Antibiotic ther-
apy has not been demonstrated to be effective in the treat-
ment of IBD, except in specific circumstances. FMT as a
treatment for IBD holds therapeutic potential and de-
serves further investigation.
Methods
Any experimental research reported in the review have
been performed with the approval of an appropriate ethics
committee and carried in compliance with the Helsinki
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